SYNTHESIS OF ISOTOPOMERS OF GEFITINIB

摘要

Gefitinib (IRESSA?, AstraZeneca ZD1839) (1) is the first in a new class of anti-cancer drugs known as Epidermal Growth Factor Receptor (EGFR) inhibitors. Gefitinib targets and blocks, within the cell, signalling pathways that are implicated in the growth and survival of cancer cells. Gefitinib was approved in Japan for the treatment of inoperable or recurrent non-small cell lung cancer in July 2002.